Pfizer, BioNTech Pop After Coronavirus Vaccines Nab Speedy Review

Pfizer, BioNTech Pop After Coronavirus Vaccines Nab Speedy Review

BioNTech and Pfizer stocks popped Monday after the duo nabbed a speedier development and review designation for two coronavirus vaccines. They plan to make 100 million doses this year.